Clinical trial NCT00059280: A Study of the Safety and Efficacy of rhGAA in Patients With Infantile-onset Pompe Disease
Official title: An Open-label, Multicenter, Multinational Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Acid Alpha-glucosidase Treatment in Patients Less Than 6 Months Old With Infantile-onset Pompe Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Glycogen Storage Disease Type II
Keywords: Pompe disease
Glycogen storage disease type II
GSD-II
Acid maltase deficiency disease
Glycogenosis 2
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2003-04-23
Enrollment: 16
Sex: ALL
Maximum age (years): 26
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: Pompe disease (also known as glycogen storage disease type II, "GSD-II") is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. This study is being conducted to evaluate the safety and effectiveness of recombinant human acid alpha-glucosidase (rhGAA) as a potential enzyme replacement therapy for Pompe disease. Patients diagnosed with infantile-onset Pompe disease who are less than or equal to 6 months old will be studied.


Eligibility criteria: Inclusion criteria:

* The patient or the patient's legal guardian(s) must provide written informed consent prior to any study-related procedures being performed;
* The patient must have clinical symptoms (documented in his or her medical record) of infantile-onset Pompe disease. In addition, the patient must have: a. an endogenous GAA activity less than 1% of the mean of the normal range as assessed in cultured skin fibroblasts; AND b. cardiomyopathy (LVMI greater than 65 g/m2) by echocardiography;
* The patient must be no older than 26 weeks and 0 days, when he/she receives the first dose of rhGAA;
* The patient and his/her legal guardian(s) must have the ability to comply with the clinical protocol.

Exclusion criteria:

* Symptoms of respiratory insufficiency, including: a. Oxygen saturation less than 90% in room air as measured by pulse oximetry; OR b. venous PCO2 greater than 55 mmHg on room air OR arterial PCO2 greater than 40 mmHg on room air; c. any ventilator use at the time of enrollment;
* Major congenital abnormality;
* Clinically significant organic disease (with the exception of symptoms relating to Pompe disease), including clinically significant cardiovascular, hepatic, pulmonary, neurologic, or renal disease, or other medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the trial or potentially decrease survival;
* Use of any investigational product within 30 days prior to study enrollment;
* Received enzyme replacement therapy with GAA from any source.

Primary outcomes:
measure: Evaluate the safety profile of MZ
timeFrame: 52 weeks
measure: To estimate the proportion of patients treated w/ MZ who were alive and free of ventilator support at 12 months of age; compared to historical cohort
timeFrame: 52 weeks
measure: Determine PK/PD profile of MZ
timeFrame: 52 weeks
measure: Determine effect of different doses of MZ on safety and efficacy
timeFrame: 52 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: University of Florida College of Medicine
state: Florida
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
city: Cincinnati
country: United States
facility: Children's Hospital Medical Center
state: Ohio
city: Salt Lake City
country: United States
facility: University of Utah Medical Center
state: Utah
city: Lyon
country: France
facility: Pediatrique Hopital deBrousse
city: Haifa
country: Israel
facility: Rambam Medical Center
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
city: Manchester
country: United Kingdom
facility: Royal Manchester Children's Hospital
Study officials:
affiliation: Genzyme, a Sanofi Company
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, Bali D, Smith SA, Li JS, Mandel H, Koeberl D, Rosenberg A, Chen YT. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010 Jan;99(1):26-33. doi: 10.1016/j.ymgme.2009.08.003.